RSV Vaccine Benefits Probably Outweigh Small Neurologic Risk, CDC Advisors Say
(MedPage Today) -- The benefits of vaccination against respiratory syncytial virus (RSV) for adults ages 60 and older probably outweigh the small risk of vaccine-related Guillain-Barré syndrome (GBS), the CDC's Advisory Committee on Immunization...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news
More News: Brain | Guillain-Barr Syndrome | Infectious Diseases | Neurology | Respiratory Medicine | Vaccines